アジェンダ
8:30 AM — 4:45 PM
9:15 AM — 9:30 AM
Welcome and Opening Remarks9:30 AM — 10:30 AM
Session 1: Keynote Address10:30 AM — 11:00 AM
11:00 AM — 12:30 PM
Session 2 Track 1: Extra-Hepatic Delivery – Clinical Experience: Emerging12:30 PM — 1:30 PM
1:30 PM — 3:00 PM
Session 3 Track 2: Translatability of CNS Safety and Pharmacology1:30 PM — 3:00 PM
Session 3 Track 3: Emerging Oligonucleotide CMC Guidance3:00 PM — 3:30 PM
3:30 PM — 5:00 PM
Session 4 Track 1 and 2: Applying Toxicology Testing to the Clinic5:00 PM — 6:00 PM
8:00 AM — 8:30 AM
8:00 AM — 4:15 PM
8:30 AM — 9:30 AM
Welcome to Day Two and Session 5: Plenary Session: CRISPR Cures9:30 AM — 10:00 AM
10:00 AM — 11:30 AM
Session 6 Track 1: Extra Hepatic Delivery – Clinical Experience in CNS10:00 AM — 11:30 AM
Session 6 Track 2: Off Target Safety Assessment10:00 AM — 11:30 AM
Session 6 Track 3: CMC Considerations in Development of mRNA-based Therapeutics11:30 AM — 12:45 PM
12:45 PM — 2:15 PM
Session 7 Track 1 and 2: Gene Editing12:45 PM — 2:15 PM
Session 7 Track 3: Challenges Around Oligonucleotides Control Strategies2:15 PM — 2:45 PM
2:45 PM — 4:15 PM
Session 8: Hot Topics4:15 PM — 5:15 PM
Oligonucleotide Safety Working Group (OSWG) – Open Meeting7:30 AM — 8:00 AM
7:30 AM — 12:40 PM
8:00 AM — 9:15 AM
Session 9 Track 2: Extra/Non-Hepatic Delivery9:25 AM — 10:40 AM
Session 10 Track 1: Clinical Pharmacology of Oligonucleotides9:25 AM — 10:40 AM
Session 10 Track 2: Non-Clinical Safety Assessment of Oligonucleotides10:40 AM — 11:10 AM
11:10 AM — 12:25 PM
Session 11: Grand Q&A Panel12:25 PM — 12:40 PM
Closing Remarks12:40 PM — 12:40 PM